^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LYN-00101

    i
    Other names: LYN-00101, LYN00101, LY00101
    Associations

    News

    Trials
    Company:
    Lynkcell
    Drug class:
    VEGF-A inhibitor, VEGFR antagonist
    Related drugs:
    Associations

    News

    Trials
    over5years
    Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 (clinicaltrials.gov)
    P1, N=0, Withdrawn, Lynkcell Inc. | N=19 --> 0 | Trial completion date: Feb 2020 --> Aug 2020 | Active, not recruiting --> Withdrawn | Trial primary completion date: Nov 2019 --> Jun 2020
    Clinical • Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
    |
    LYN-00101